What diseases are ruxolitinib tablets/Jiekewei used to treat?

Ruxolitinib tablets/Ruxolitinib (Ruxolitinib) is an oral JAK1/2 inhibitor. As an important breakthrough in the treatment of blood system and immune-related diseases in the past decade, it is widely used in the management of a variety of serious diseases. It first made breakthroughs in the field of myelofibrosis, and its current indications have expanded to many types of blood and immune diseases.

Ruxolitinib is mainly used to treat adult patients with intermediate-risk or high-risk primary myelofibrosis (PMF), myelofibrosis secondary to polycythemia vera (PPV-MF), and myelofibrosis secondary to essential thrombocythemia (PET-MF). Myelofibrosis is a rare but serious hematopoietic stem cell disease characterized by splenomegaly, impaired bone marrow hematopoietic function, and a series of systemic symptoms. By inhibiting the abnormal JAK signaling pathway, ruxolitinib can help improve splenomegaly, relieve patients' symptoms such as fatigue, night sweats, and weight loss, and improve their quality of life.

Ruxolitinib also plays an important role in the treatment of graft-versus-host disease (GVHD). Ruxolitinib has become an important treatment option for patients 12 years of age and older with acute GVHD or chronic GVHD who have not responded to glucocorticoids or other systemic treatments. GVHD is a common and serious complication after hematopoietic stem cell transplantation. Traditional treatment is mainly glucocorticoids, but many patients have limited efficacy. The emergence of ruxolitinib provides new hope for these refractory patients.

In addition to the approved indications, ongoing overseas studies are also exploring the potential value of ruxolitinib in other inflammatory and immune diseases, such as certain refractory skin diseases, autoimmune diseases, etc. As research deepens, its application fields are expected to be further expanded.

In summary, ruxolitinib tablets are mainly used in the clinical treatment of myelofibrosis and graft-versus-host disease, and have brought tangible survival benefits to patients. It is not only an important breakthrough for rare blood diseases, but also marks an important progress in targeted therapy in the management of immune diseases.

Reference materials:https://www.jakavi.com/